What did @emily.dunnam actually say?
She said it plainly: she started Wegovy in June 2023 at 160 pounds, stopped injections in January 2024, and by March 2024 weighed between 115 and 118 pounds. That is a loss of roughly 42 to 45 pounds over about seven months of active treatment. She also claims she is maintaining that weight through exercise and diet alone, without continued medication.
She did not make any outrageous medical claims. She did not tell viewers what dose to take, promise anyone else the same result, or suggest Wegovy cures anything. She acknowledged physical changes like stretch marks and loose skin with refreshing honesty. The video reads more like a personal diary entry than a health influencer pitch, which matters when evaluating what kind of influence it might have on viewers.
Does the science back this up?
The weight loss figure is plausible but sits at the higher end of what clinical trials typically show. The maintenance claim after stopping is where things get genuinely complicated, and that complexity deserves more than a passing mention.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants lost an average of 14.9 percent of body weight on semaglutide 2.4mg over 68 weeks. For a 160-pound starting weight, that math lands around 24 pounds on average, not 42. Her result is not impossible, it is just above the average. Individual variation is real. The STEP 5 trial confirmed efficacy over two years, but it also confirmed something else: the STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism) found that one year after stopping semaglutide, participants regained two-thirds of their lost weight on average. Her confidence that she can maintain without the drug is optimistic, and the data suggests she should be cautious.
What did they get wrong (or right)?
She got the personal honesty right. She got the timelines right. What she underplays, possibly without knowing it, is the rebound risk after discontinuation.
Saying she has "all the confidence in the world" she can maintain is not a lie, but it is not well-supported by the evidence either. The STEP 1 extension data is fairly blunt: GLP-1 receptor agonists appear to work in large part because they suppress appetite through ongoing receptor activity. Remove the drug and that mechanism disappears. Diet and exercise can help, and her habits sound solid, but they are fighting against a biology that is no longer being assisted. She is also only about two months post-discontinuation at the time of filming. That is not enough time to know if maintenance will hold. To her credit, she did not tell anyone to stop their medication. She only described her own choice.
What should you actually know?
The broader context here matters. Wegovy is a once-weekly injectable semaglutide at 2.4mg, FDA-approved specifically for chronic weight management. It is not a short-term fix by design. The clinical evidence supports it as a long-term tool, not a seven-month reset button.
If you are watching this video and thinking about stopping your own prescription after hitting a goal weight, talk to your prescriber first. The SURMOUNT and STEP trial data both point toward ongoing treatment being necessary for most people to sustain results. Some individuals do maintain after stopping, but they appear to be the exception rather than the rule. Her experience may be genuinely real and may hold. It may also be two months into a slow regain that has not shown up yet. The science cannot tell her story for her, but it does suggest that "confidence" is not the same as a clinical plan.
- Weight loss of 42 to 45 pounds on semaglutide is above average but within the range of reported outcomes
- Stopping GLP-1 medication does not mean the weight loss is permanent
- Any decision to discontinue should involve a licensed prescriber, not a TikTok timeline